One company is atypical in the industry for its use of patient and caregiver input to guide its drug-development journey. That shows in the program for its lead drug entering later-stage trials in treating Alzheimer’s disease.
The story of the business challenges faced by Diasome Pharmaceuticals as it develops its insulin-enhancing delivery technology, which seeks to correct a long-known deficiency in subcutaneous injection of insulin.
Bioharmony Therapeutics is developing novel, “lysin-based” antimicrobials. The company is out to change the world of antibiotics, not by tweaking an old formula, but by advancing an entirely new mode of action.
Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.
Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.
An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.
This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.
Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.
Garo Armen, CEO of Agenus and a long-time pharma industry veteran, has shown the instincts for simple money-making on one hand and the humanitarian side of biopharma on the other.
Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.
An in-depth look at the career and accomplishments of Howard Fillit, M.D., who has long led the exploration of Alzheimer’s disease outside and inside of the biopharma industry.
Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.
At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.
An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.